Agent based modeling of relapsing multiple sclerosis: a possible approach to predict treatment outcome

In this work, we present the application of a computational modeling infrastructure named UISS (Universal Immune System Simulator) able to simulate the main features and dynamics of the immune system activities. We provide an extended version of UISS to simulate all the underlying MS pathogenesis and its interaction with the host immune system. We simulated MS patients with different relapsing-remitting courses. Even though the model can be further personalized employing immunological parameters and genetic information, based on the available data, we obtained simulation scenarios for each patient who matched the real clinical and MRI history. UISS may have the potential to assist MS specialists in predicting the course of the disease and the response to treatment.

[1]  J. Correale,et al.  Is it time for a new global classification of multiple sclerosis? , 2014, Journal of the Neurological Sciences.

[2]  Francesco Pappalardo,et al.  Agent based modeling of the effects of potential treatments over the blood-brain barrier in multiple sclerosis. , 2015, Journal of immunological methods.

[3]  Francesco Topputo,et al.  Induction of T-cell memory by a dendritic cell vaccine: a computational model , 2014, Bioinform..

[4]  S. Dhib-jalbut,et al.  Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis , 2002, Neurology.

[5]  F. Pappalardo,et al.  In silico modeling and in vivo efficacy of cancer-preventive vaccinations. , 2010, Cancer research.

[6]  S. Sánchez-Ramón,et al.  Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing−remitting multiple sclerosis , 2007, Journal of Neuroimmunology.

[7]  Luigi Murri,et al.  Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis , 2008, Neuropsychiatric disease and treatment.

[8]  L. Fugger,et al.  Immunomodulation in multiple sclerosis: promises and pitfalls. , 2017, Current opinion in immunology.

[9]  F. Tang,et al.  The Primate-Specific Gene TMEM14B Marks Outer Radial Glia Cells and Promotes Cortical Expansion and Folding. , 2017, Cell stem cell.

[10]  A. Compston,et al.  Multiple sclerosis. , 2002, Lancet.

[11]  Alessandro Lombardo,et al.  A computational model to predict the immune system activation by citrus-derived vaccine adjuvants , 2016, Bioinform..

[12]  S. Bonavita,et al.  Cognitive impairment and memory disorders in relapsing–remitting multiple sclerosis: the role of white matter, gray matter and hippocampus , 2015, Journal of Neurology.

[13]  Süleyman Kaplan,et al.  Purkinje cell number decreases in the adult female rat cerebellum following exposure to 900MHz electromagnetic field , 2010, Brain Research.

[14]  Francesco Pappalardo,et al.  Mathematical modeling of biological systems , 2013, Briefings Bioinform..

[15]  Abdul Mateen Rajput,et al.  Computational modeling of brain pathologies: the case of multiple sclerosis , 2016, Briefings Bioinform..

[16]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[17]  M. Sospedra,et al.  Immunology of Multiple Sclerosis , 2016, Seminars in Neurology.

[18]  P. Calabresi,et al.  Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale , 2005, Neurology.

[19]  L. Kappos,et al.  MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS , 2007, Neurology.